Immunotherapy use in oesophagogastric cancers—a review of the literature

Annabel Smith, Amitesh Roy, Christos S. Karapetis, Vy Broadbridge, Timothy Price

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancers of the upper gastrointestinal tract are a leading cause of cancer-related death world-wide and historically have a poor prognosis. The incidence and histology of these cancers have varied temporally and geographically over the last three decades, with an emerging understanding of the differences in the molecular and genetic profiles across different subgroups. Management of oesophagogastric cancers is by a multidisciplinary team with utilisation of surgery, radiotherapy and systemic treatments in combinations where appropriate. Immune checkpoint inhibition (ICI) has drastically changed the treatment landscape of multiple solid malignancies in the last 5 years. In oesophagogastric cancer, clinical trials have only recently shown activity that is often associated with the molecular characteristics of these tumours, in particular PD-L1 scores or microsatellite instability (MSI-H). This review looks to present the pivotal trials in this space, discuss the complexities between trials that may explain the disparate results and assess the benefit ICI offers in the treatment landscape at present.

Original languageEnglish
Pages (from-to)21-29
Number of pages9
JournalBritish Journal of Cancer
Volume127
Issue number1
Early online date8 Mar 2022
DOIs
Publication statusPublished - 1 Jul 2022

Keywords

  • Cancer immunotherapy
  • Gastric cancer
  • Oesophageal cancer

Fingerprint

Dive into the research topics of 'Immunotherapy use in oesophagogastric cancers—a review of the literature'. Together they form a unique fingerprint.

Cite this